Europe Deep Brain Stimulation Devices Market - 2023-2030

Europe Deep Brain Stimulation Devices Market - 2023-2030

Market Overview

The Europe Deep brain stimulation devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Deep brain stimulation (DBS) gives a little electrical current to a particular brain region. Several conditions can be helped by the current's electricity, which activates the brain cells there. The current travels to the brain through one or more cables connected to a small implanted device placed beneath the skin and around the collarbone. Movement abnormalities, mental health issues, and epilepsy are just a few of the ailments that DBS can treat.

Market Dynamics

The major factors driving the Europe Deep brain stimulation devices market are increasing demand for products involving deep brain stimulation, the rising incidence of neurological diseases and periodical authorization and introduction of novel devices.

Increasing demand for products involving deep brain stimulation is expected to drive the market’s growth.

A significant market driver is the rising incidence of neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy. In the EU, neurological illnesses are the third most frequent cause of incapacity and early mortality. As the population of Europe ages, it is probable that both their frequency and burden will rise. Health authorities need to pay more attention to neurological illnesses in prevention and treatment.

The European Parkinson's Disease Association, for instance, claims that Parkinson's is a very individual disorder that varies from person to person and necessitates a customized approach to therapy and care. Parkinson's disease affects more than 1.2 million individuals in Europe now, and by 2030, that number is expected to triple. It is concerning that the prevalence of Parkinson's disease is rising globally and that during the next 20 years, it will double (affecting up to 2% of persons over 60 and 6% of those over 80).

In Europe, the average cost per patient with Parkinson's disease is around €11,000. This results in an annual cost to Europe of €13.9 billion. As the condition worsens, the cost per person per year also rises, and non-motor symptoms are a primary cause of hospitalization and institutionalization, two important cost drivers in Parkinson's care.

High cost of equipment will expected to hamper the market’s growth.

However, movement abnormalities are treated by deep brain stimulation (DBS). To determine how cost-effective DBS is, the highest level economic evaluations (EEs) are required. The entire cost of treatment for DBS, including the battery replacement the neurostimulator device requires, is €53,217. The cost issue is particularly problematic in impoverished countries, where few people can afford the hardware and treatment fees, despite the high frequency of movement disorders and other illnesses that can be treated with DBS. The lack of surgical equipment and knowledge may still be a challenge, but if low-cost IPGs develop further, this problem may be minimized.

COVID-19 Impact Analysis

All patients, including those with Parkinson's disease (PD) treated with deep brain stimulation, were adversely affected by COVID-19 pandemic shutdowns (DBS). Hospitals delayed elective operations, including initial DBS device installation and implanted pulse generator (IPG) replacements for exhausted batteries because they were overloaded with COVID-19 cases. The most popular surgical procedure for PD patients is DBS, with thousands of implantations occurring yearly in Europe.

The COVID-19 pandemic has expedited healthcare's transition to digital technology. Many nations, including Hungary, have adopted telemedicine. Teleprogramming has yet to be improved in the cases of the roughly 1000 Hungarian patients with movement MDs treated with DBS to finish the important parts of neurological care. Remote programming has previously been proven to be a quick and effective method for continuing to administer DBS therapy during COVID-19.

Abbott has been the first among DBS device manufacturers to introduce a new technology (NeuroSphere) that enables patients to contact their neurologists and obtain DBS modifications from home or another location with WiFi or cellular access. After receiving the CE mark and Food and Drug Administration approval, this innovation began to be utilized in the United States and other European nations, including the United Kingdom, Ireland, and Germany.

Segment Analysis

Hospitals segment is expected to grow at the fastest CAGR during the forecast period (2022-2030)

The end user segment market share for DBS devices is anticipated to be high. The primary end-user is a hospital since they offer superior care to patients with neurological problems. They offer superior assistance, care, and a range of therapeutic choices. Several doctors typically collaborate to create a comprehensive treatment plan for patients that incorporate a variety of treatments. This interdisciplinary team is of the greatest priority for those with neurological diseases.

Neurosurgeons insert one or more leads during the procedure into the brain. A connection between these leads and an extension wire creates a link between the leads and electrodes of a tiny neurostimulator (internal pulse generator). The doctor programs the neurostimulator to provide electrical signals a few weeks after it is implanted. This programming process may require more than one visit in a week or month for the neurostimulator to appropriately regulate the current and deliver results. While adjusting the device, the doctor is mindful of striking the ideal balance between minimizing the negative effects and enhancing the symptoms. The segments drive the market for all these factors.

Geographical Analysis

Germany holds the largest market share in the Europe Deep brain stimulation devices market.

Germany dominates the Europe Deep brain stimulation devices market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 250,000 people in Germany have Parkinson's disease, according to the German Parkinson Association. Over 80,000 people utilize deep brain stimulation globally, with Parkinson's disease accounting for about two-thirds of users. The device is also known as a ""brain pacemaker"" in common parlance. Deep brain stimulation also treats anxiety, severe depression, and obsessive-compulsive disorder.

Clinical trials are also undertaken in other fields, such as the treatment of Alzheimer's illness and Tourette syndrome. Previous studies with non-human primates are essential, especially when introducing novel therapeutic techniques, to rule out any potential harm to patients and the emergence of unexpected side effects.

This kind of treatment can benefit humans without having negative effects through brain implantation. Deep brain stimulation's precise target area was discovered through the neuroscientific study of the structure and function of non-human primates' brains. The findings from studies with monkeys also served as the foundation for electrode technology and implantation techniques. According to the Freiburg University Clinic, which frequently performs these procedures, only 2% of all difficulties are related to the surgery itself.

Competitive Landscape

The Deep brain stimulation devices market is moderately competitive with local and Europe companies’ presence Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, AlevaNeurotherapeutics SA, Functional Neuromodulation Ltd., Cyberonics, Inc, LivaNova PLC, Nevro Corporation. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in January 2020, the deep brain stimulation device Percept from the medical technology behemoth Medtronic has just been given the European CE Mark. A well-known medical technique called deep brain stimulation produces electrical signals that can reduce symptoms of Parkinson's disease, epilepsy, OCD, and other diseases.

Abbott Laboratories.

Overview:Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Infinity DBS System: Infinity DBS is the first directional DBS system that has been approved for all key targets that are used for treatments like movement disorders, Parkinson's disease and Essential Tremor.

Europe Deep brain stimulation devices market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.